Dr. Lewis on New and Emerging Treatments for Melanoma

Karl Lewis, MD
Published: Monday, Oct 21, 2013

Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses new and emerging treatments for metastatic melanoma.

Lewis says the list of new and emerging treatments for metastatic melanoma has grown due to the tremendous advancements in the field over the last couple of years.

In the immunotherapy field, Lewis says, ipilimumab showed a survival advantage for the first time in patients with melanoma. Progress is also being made with the development of PD-1 antibodies and PD-1 ligand antibodies.

There have also been developments in molecular targeted therapies, Lewis say, including agents targeting the RAS/RAF pathway, BRAF inhibitors, and MEK inhibitors.
Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses new and emerging treatments for metastatic melanoma.

Lewis says the list of new and emerging treatments for metastatic melanoma has grown due to the tremendous advancements in the field over the last couple of years.

In the immunotherapy field, Lewis says, ipilimumab showed a survival advantage for the first time in patients with melanoma. Progress is also being made with the development of PD-1 antibodies and PD-1 ligand antibodies.

There have also been developments in molecular targeted therapies, Lewis say, including agents targeting the RAS/RAF pathway, BRAF inhibitors, and MEK inhibitors.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x